Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Gilead Buys Arresto For $225 Million

by Rick Mullin
January 3, 2011 | A version of this story appeared in Volume 89, Issue 1

Gilead Sciences will acquire Arresto Biosciences, a development-stage biotech company in Palo Alto, Calif., that focuses on fibrotic diseases and cancer. Gilead will pay $225 million and make unspecified future payments based on sales achievements. Arresto’s lead drug candidate, the monoclonal antibody AB0024, is in Phase I trials for the treatment of idiopathic pulmonary fibrosis (IPF) and advanced solid tumors. The acquisition is the first foray for Gilead, historically focused on small molecules, into the development of monoclonal antibodies.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.